Form 4: Corbus Pharmaceuticals Grants Equity Awards to Director

Director Brent Pfeiffenberger received 7,500 restricted stock units and 24,700 stock options as part of the company's 2024 Equity Compensation Plan.

Summary

• Brent Pfeiffenberger, a member of the Board of Directors, was granted 7,500 restricted stock units (RSUs) on May 19, 2026.
• The director also received 24,700 stock options with an exercise price of $9.15 per share.
• Both the RSUs and the stock options are scheduled to vest in three equal annual installments starting one year from the grant date.
• The stock options have a ten-year term, expiring on May 19, 2036.
• Following these transactions, the reporting person directly owns 7,500 shares of common stock (represented by unvested RSUs) and 24,700 derivative securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing for director compensation that maintains the status quo of board alignment without signaling major strategic shifts.

Positives

• Aligns director compensation with long-term shareholder value through equity-based incentives.
• Three-year vesting schedule encourages long-term commitment and retention of board expertise.
• The exercise price of $9.15 sets a clear benchmark for internal expectations of share price appreciation.

Negatives

• The issuance of new equity awards represents potential future dilution for existing shareholders.
• The value of the compensation is tied to market performance, which may be volatile in the pharmaceutical sector.

Risks

• Vesting is contingent upon continued service to the company through 2029.
• The stock options will provide no value to the holder if the market price remains below the $9.15 exercise price.

Future Outlook

The multi-year vesting schedule indicates a focus on long-term board stability and alignment with corporate milestones through at least May 2029.

Management Comments

• The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the biotechnology and pharmaceutical industries to conserve cash while ensuring leadership is incentivized to drive clinical and regulatory success.

Comparison to Industry Standards

• The three-year vesting period is consistent with mid-cap biotech peers such as Viking Therapeutics and Madrigal Pharmaceuticals.
• The use of both RSUs and options is a common balanced approach to director remuneration in the NASDAQ Biotechnology Index.

Corporate Governance

Related Party Transactions

• Grant of equity awards to a member of the Board of Directors as part of standard compensation.

Stakeholder Impact

• Shareholders may experience minor dilution as these awards vest and options are exercised.
• The Board of Directors maintains a vested interest in the company's long-term stock price performance.

Next Steps

• First vesting of equity awards on May 19, 2027.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Director Compensation, Equity Incentive Plan, Brent Pfeiffenberger